|
´ëÇѾÏÇÐȸ°¡ ¼±Á¤, ¼ö¿©ÇÏ´Â Á¦3ȸ '±¤µ¿ ¾ÏÇмú»ó' ¼ö»óÀÚ·Î ¿ï»êÀÇ´ë ³»°ú °À±±¸ ±³¼ö¿Í ¿¬¼¼ÀÇ´ë º´¸®Çб³½Ç ±èÈ£±Ù ±³¼ö, ¼¿ïÀÇ´ë ³»°ú ÀÓ¼®¾Æ ±³¼ö°¡ ¼±Á¤µÆ´Ù.
´ëÇѾÏÇÐȸ´Â 20ÀÏ ¼¿ï ¼Ò°øµ¿ ·Ôµ¥È£ÅÚ¿¡¼ Á¦40ȸ Á¤±âÃÑȸ¸¦ ¿°í À̵é 3¸í¿¡°Ô ¾ÏÇмú»óÀ» ¼ö¿©Çß´Ù.
´ëÇѾÏÇÐȸ¿Í ±¤µ¿Á¦¾àÀÌ °øµ¿ Á¦Á¤ÇÑ '±¤µ¿ ¾ÏÇмú»ó'Àº ¼öÁØ ³ôÀº SCI Àú³Î ȤÀº ºÐ¾ßº° ±ÇÀ§ÀÖ´Â ÇÐȸÁö¿¡ ³í¹®À» ¹ßÇ¥ÇÑ ¿¬±¸ÀÚ¸¦ ´ë»óÀ¸·Î ¼ö»óÀÚ¸¦ ¼±Á¤ÇÑ´Ù. °¢°¢ 500¸¸¿øÀÇ »ó±Ý°ú »óÀåÀÌ ¼ö¿©µÈ´Ù.
ÃÖ°í ¿µÇâ·ÂÁö¼ö(IF, Impact Factor) SCI Àú³ÎÀÇ Àӻ󿬱¸ ³í¹® ¹ßÇ¥ ºÎ¹®¿¡¼´Â °À±±¸ ±³¼ö°¡ Lancet Oncol(IF 25.12) ÇмúÁö¿¡ ³í¹®(Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial)À» °ÔÀçÇÑ ¹Ù ÀÖ´Ù.
±âÃÊ¿¬±¸ ³í¹® ¹ßÇ¥ ºÎ¹®¿¡¼´Â ±èÈ£±Ù ±³¼ö°¡ Clin Cancer Res(IF 7.837) ÇмúÁö¿¡ ³í¹®(Protein Kinase C-delta-Mediated Recycling of Active KIT in Colon Cancer)À» °ÔÀçÇß´Ù.
ÀÓ¼®¾Æ ±³¼ö´Â ¸ðµÎ 6ÆíÀÇ SCI Àú³Î¿¡ ´ëÇѾÏÇÐȸÁö¸¦ Àοë, ³í¹®À» °ÔÀçÇÔÀ¸·Î½á ±¹³» ÃÖ°í ±ÇÀ§ÀÇ ¾ÏÇÐȸÁö°¡ ¸í½Ç»óºÎ ±¹Á¦Àú³Î·Î µµ¾àÇϴµ¥ ±â¿©Çß´Ù´Â ÆòÀÌ´Ù.
¾ÏÇÐȸ °ü°èÀÚ´Â ¡°ÇÐȸ ⸳ 40ÁÖ³âÀ» ±â³äÇÏ´Â ÀÚ¸®¿¡¼ ¾Ï Ä¡·áºÐ¾ßÀÇ ±âÃÊ-ÀÓ»ó ¿¬±¸¿¡ ¸¹Àº ±â¿©¸¦ ÇÑ È¸¿øµé¿¡°Ô ¶æ ±íÀº »óÀ» ¼ö¿©ÇÏ°Ô µÅ ±â»Ú´Ù¡±¸ç ¡°ÇâÈÄ¿¡µµ Çѱ¹ÀÇÇÐÀÇ ±¹Á¦Àû À§»ó Á¤¸³¿¡ ±â¿©ÇÒ ¼ö Àֱ⸦ ±â´ëÇÑ´Ù"°í ¸»Çß´Ù. |